Acura Pharmaceuticals (Acura Pharmaceuticals) Inventory-to-Revenue : 0.00 (As of Dec. 2021)

View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Acura Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2021 was $0.00 Mil. Acura Pharmaceuticals's Revenue for the three months ended in Dec. 2021 was $0.04 Mil. Acura Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2021 was 0.00.

Acura Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2021 stayed the same from Sep. 2021 (0.00) to Sep. 2021 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Acura Pharmaceuticals Inventory-to-Revenue Historical Data

The historical data trend for Acura Pharmaceuticals's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acura Pharmaceuticals Inventory-to-Revenue Chart

Acura Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Inventory-to-Revenue

Get a 7-Day Free Trial

0.10

Acura Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Acura Pharmaceuticals's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acura Pharmaceuticals's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Acura Pharmaceuticals's Inventory-to-Revenue falls into.

Acura Pharmaceuticals Inventory-to-Revenue Calculation

Acura Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

	Inventory-to-Revenue (A: Dec. 2021 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2020 )	+	Total Inventories (A: Dec. 2021 ))	/	count )	/	Revenue (A: Dec. 2021 )
=	( (0	+	0)	/	1 )	/	1.563
=	0					/	1.563
=	0.00

Acura Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2021 is calculated as

	Inventory-to-Revenue (Q: Dec. 2021 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2021 )	+	Total Inventories (Q: Dec. 2021 ))	/	count )	/	Revenue (Q: Dec. 2021 )
=	( (0	+	0)	/	1 )	/	0.036
=	0					/	0.036
=	0.00

Acura Pharmaceuticals (OTCPK:ACUR) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Acura Pharmaceuticals's Days Inventory for the three months ended in Dec. 2021 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2021 )	/	Cost of Goods Sold (Q: Dec. 2021 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Acura Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2021 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2021 )	/	Average Total Inventories (Q: Dec. 2021 )
	=	0	/	0
	=

Acura Pharmaceuticals Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

616 N. North Court, Suite 120, Palatine, IL, USA, 60067

Website

http://www.acurapharm.com

Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.

Executives

Bruce F Wesson	director	1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly	director	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross	director	1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh	officer: VP, Corporate Development
Immanuel Thangaraj	director	10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser	officer: VP, Treasurer & Controller	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones	officer: President & CEO	C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko	officer: VP Pharmaceutical Sciences APT	C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens	officer: Senior VP & CFO	C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc	10 percent owner	333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc	10 percent owner	C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte	10 percent owner	9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P	10 percent owner	610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc	10 percent owner	680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp	10 percent owner	610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020